# Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer

> **NCT07484022** · PHASE1 · RECRUITING · sponsor: **Generate Biomedicines** · enrollment: 37 (estimated)

## Conditions studied

- Advanced Urothelial Cancer
- Metastatic Urothelial Carcinoma

## Interventions

- **DRUG:** GB-4362
- **DRUG:** enfortumab vedotin (EV)
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT07484022
- **Lead sponsor:** Generate Biomedicines
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04
- **Primary completion:** 2027-06
- **Final completion:** 2027-12
- **Target enrollment:** 37 (ESTIMATED)
- **Last updated:** 2026-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07484022

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07484022, "Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07484022. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*